All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
PXS-5505: Investigational New Drug application has been submitted to the FDA
Bookmark this article
Following the recent U.S. Food and Drug Administration (FDA) orphan drug designation, an Investigational New Drug (IND) application has been submitted for a phase I/II study of PXS-5505, a pan-lysyl oxidase (LOX) inhibitor, which is currently under development for the treatment of myelofibrosis.
PXS-5505 has been previously tested in healthy volunteers in a phase I study. The IND submission protocol covers a dose escalation study for 1 month, and an open-label, 6-month treatment phase in patients who are not receiving a Janus kinase inhibitor. The study is planned to be started by the end of 2020 and be completed in 2022.
Inhibition of LOX family members is expected to show benefits of reduced fibrotic burden and to have favorable effects on aberrant blood cell production seen in myelofibrosis.
- Pharmaxis submits Investigational New Drug application for treatment of myelofibrosis. https://www.proactiveinvestors.com.au/companies/news/924874/pharmaxis-submits-investigational-new-drug-application-for-treatment-of-myelofibrosis-924874.html. Published Jul 23, 2020. Accessed Jul 23, 2020.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox